Clinical Trial: A Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Efficacy of YXC-001 in Participants with Advanced Solid Tumors (China)

China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Efficacy of YXC-001 in Participants with Advanced Solid Tumors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133398

Registration Time: 2026/09/25

Type: Interventional study

Primary Sponsor: Shanghai Chest Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343880

Published by HT Digital Content Services with permission from Health Daily Digest....